{"title":"Related pathological factors in treatment and prognosis of diffuse large B-cell lymphoma","authors":"Zhe Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.001","DOIUrl":null,"url":null,"abstract":"Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin′s lymphoma (NHL), DLBCL comprised about 1/3 of all NHL cases. DLBCL is a kind of highly aggressive neoplasm. Precise diagnosis of DLBCL was only made by combination of morphological, immunophenotype and clinical manifestations evidence. In recent decade, molecular study of DLBCL progresses very rapidly, the new advances promoted the prognosis prediction and treatment strategy of DLBCL. In this paper, we will focus on the important pathological issues for the treatment and prognosis prediction of DLBCL, for examples, pathologic subtype, morphology, cell of origin, genetic alteration, immunophenotype and tumor immune micro-enviroment. \n \n \nKey words: \nLymphoma, B-cell; Lymphoma, large B-cell, diffuse; Tumor microenviroment; Genetic alteration; Cell of origin","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"185-188"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin′s lymphoma (NHL), DLBCL comprised about 1/3 of all NHL cases. DLBCL is a kind of highly aggressive neoplasm. Precise diagnosis of DLBCL was only made by combination of morphological, immunophenotype and clinical manifestations evidence. In recent decade, molecular study of DLBCL progresses very rapidly, the new advances promoted the prognosis prediction and treatment strategy of DLBCL. In this paper, we will focus on the important pathological issues for the treatment and prognosis prediction of DLBCL, for examples, pathologic subtype, morphology, cell of origin, genetic alteration, immunophenotype and tumor immune micro-enviroment.
Key words:
Lymphoma, B-cell; Lymphoma, large B-cell, diffuse; Tumor microenviroment; Genetic alteration; Cell of origin
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
